Ran Cui
Impact in
- Cancer Research top 10%
- Cancer-related molecular mechanisms research
- MicroRNA in disease regulation
- Molecular Medicine top 10%
- Curcumin's Biomedical Applications
Papers in
-
- Cancer-related molecular mechanisms research 3
- Cancer, Hypoxia, and Metabolism 2
- Oncology 9
- Pancreatic and Hepatic Oncology Research 4
- Cancer Immunotherapy and Biomarkers 2
- Co-authors
- Ben Yue (4 shared papers)Chenlong Song (3 shared papers)Linxi Yang (1 shared paper)Zizhen Zhang (1 shared paper)Gang Zhao (1 shared paper)Ming Zhong (9 shared papers)Yiwei Wang (2 shared papers)Jin-Jin Lin (1 shared paper)
- Journals
- Journal of Laparoendoscopic & Advanced Surgical Techniques (3 papers)Molecular Therapy — Nucleic Acids (2 papers)Frontiers in Oncology (2 papers)Frontiers in Immunology (2 papers)Cancer Management and Research (1 paper)
- Partner nations
- ChinaUnited States
In The Last Decade
Ran Cui
22 papers receiving 968 citations
Ran Cui's Hit Papers
Peers
Comparison fields: 5 of 73
- Cancer Research 231
- Molecular Medicine 65
- Molecular Biology 511
- Drug Discovery 2
- Oncology 85
Countries citing papers authored by Ran Cui
This map shows the geographic impact of Ran Cui's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ran Cui with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ran Cui more than expected).
Fields of papers citing papers by Ran Cui
This network shows the impact of papers produced by Ran Cui. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ran Cui. The network helps show where Ran Cui may publish in the future.
Co-authors
The 25 scholars most cited alongside Ran Cui, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 25 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | METTL3-mediated N6-methyladenosine modification is critical for epithelial-mesenchymal transition and metastasis of gastric cancer Hit paper breakdown → | 2019 | 478 |
| 2 | 2018 | 162 | |
| 3 | 2016 | 131 | |
| 4 | 2019 | 37 | |
| 5 | 2021 | 30 | |
| 6 | 2021 | 26 | |
| 7 | 2018 | 25 | |
| 8 | 2019 | 15 | |
| 9 | 2018 | 14 | |
| 10 | 2016 | 11 | |
| 11 | 2021 | 10 | |
| 12 | 2025 | 8 | |
| 13 | 2020 | 7 | |
| 14 | 2022 | 6 | |
| 15 | 2022 | 6 | |
| 16 | 2019 | 4 | |
| 17 | 2023 | 4 | |
| 18 | 2025 | 3 | |
| 19 | Expression of CHD5 may serve as an independent biomarker of prognosis in colorectal cancer via immunohistochemical staining. | 2018 | 2 |
| 20 | 2022 | 2 |
About Ran Cui
Ran Cui is a scholar working on Cancer Research, Oncology, Ophthalmology, Pathology and Forensic Medicine and Molecular Biology, having authored 25 papers that have together received 984 indexed citations. Recurring topics across this work include Pancreatic and Hepatic Oncology Research (4 papers), Cancer-related molecular mechanisms research (3 papers), Cancer, Hypoxia, and Metabolism (2 papers), Ocular Oncology and Treatments (2 papers), Cancer Immunotherapy and Biomarkers (2 papers), Nanoplatforms for cancer theranostics (2 papers), Genetic factors in colorectal cancer (2 papers) and PI3K/AKT/mTOR signaling in cancer (2 papers). The work is most often cited by research in Cancer Research (231 citations), Molecular Medicine (65 citations), Molecular Biology (511 citations), Drug Discovery (2 citations) and Oncology (85 citations). Ran Cui has collaborated with scholars based in China and United States. Frequent co-authors include Ben Yue, Chenlong Song, Linxi Yang, Zizhen Zhang, Gang Zhao, Ming Zhong, Yiwei Wang, Jin-Jin Lin, Xianting Ding and Jiayi Yu. Their work appears in journals such as Journal of Laparoendoscopic & Advanced Surgical Techniques, Molecular Therapy — Nucleic Acids, Frontiers in Oncology, Frontiers in Immunology and Cancer Management and Research.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.